NRG Oncology Data Monitoring Committees

NRG DMC Panels A, B, and C

• Met Mon/Tues, July 10-11, reviewed 61 trial reports (phase IIR, II/III, III trials)
  o Progress updates on accruing studies
  o Review of accrued studies not yet reported
  o Review of protocol specified interim analyses

- Minutes will be posted on CTSU, PIs advised of recommendations shortly
Trial Accrual & Development

• **Grant Year Totals (intervention, accrual to NRG trials):**

  • 2021-22: 2,924
  • 2022-23: 3,713
  • 2023: 1,582 (March 1 – June 30)
    (projection ~3,800)

• **New trial development:**
  • 5 activations so far in 2023
  • 8 SC-approved trials with 2023 activation dates
  • 11 activations in 2022
  • Combo-MATCH: 1st 2 trials (breast, ovarian/endometrial) – launched!
NRG Ops/SDMC Initiatives 2023

1) **Clinical Trial Streamlining** – NCI Working Group meetings are proceeding – recommendations by 2024 – NCI will lead implementation

2) **NRG Quarterly Performance Report Card** – Updated to include a tab for data delinquency, outstanding queries, and case completeness by Protocol

3) **Summarization/tracking** of enrollment diversity in NRG trials
SDMC Initiatives 2023
Trial Enrollment Diversity

Population-representative sampling into NRG trials is critical for:

- Relevance, generalizability of findings
- Evidence of trial accessibility, identification of barriers to enrollment
- Potential to identify differential benefits of interventions

*Seeking and reporting on accrual diversity are a mandate of federal awards since 1993*
## NRG Enrollment Demographics 2014-2023

<table>
<thead>
<tr>
<th>Disease Committee</th>
<th>Race Group</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>White</td>
<td>Black</td>
<td>Asian</td>
<td>Native AM/AK</td>
<td>Hawaiian /PI</td>
<td>Multi group</td>
<td>Unknown</td>
<td>All Pts</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>%</td>
<td>N</td>
<td>%</td>
<td>N</td>
<td>%</td>
<td>N</td>
<td>%</td>
<td>N</td>
<td>%</td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>Brain</td>
<td>1040</td>
<td>82.3</td>
<td>58</td>
<td>4.6</td>
<td>73</td>
<td>5.8</td>
<td>4</td>
<td>0.3</td>
<td>4</td>
<td>0.3</td>
<td>85</td>
<td>6.7</td>
<td>1264</td>
</tr>
<tr>
<td>Breast</td>
<td>3816</td>
<td>76.0</td>
<td>653</td>
<td>13.0</td>
<td>296</td>
<td>5.9</td>
<td>31</td>
<td>0.6</td>
<td>17</td>
<td>0.3</td>
<td>18</td>
<td>0.4</td>
<td>191</td>
</tr>
<tr>
<td>Gynecologic</td>
<td>6792</td>
<td>74.2</td>
<td>746</td>
<td>8.2</td>
<td>1154</td>
<td>12.6</td>
<td>91</td>
<td>1.0</td>
<td>25</td>
<td>0.3</td>
<td>17</td>
<td>0.2</td>
<td>323</td>
</tr>
<tr>
<td>GI</td>
<td>1250</td>
<td>80.7</td>
<td>105</td>
<td>6.8</td>
<td>91</td>
<td>5.9</td>
<td>11</td>
<td>0.7</td>
<td>4</td>
<td>0.3</td>
<td>1</td>
<td>0.1</td>
<td>86</td>
</tr>
<tr>
<td>GU</td>
<td>3824</td>
<td>77.8</td>
<td>792</td>
<td>16.1</td>
<td>99</td>
<td>2.0</td>
<td>10</td>
<td>0.2</td>
<td>9</td>
<td>0.2</td>
<td>6</td>
<td>0.1</td>
<td>176</td>
</tr>
<tr>
<td>Head &amp; Neck</td>
<td>1935</td>
<td>68.9</td>
<td>157</td>
<td>5.6</td>
<td>529</td>
<td>18.8</td>
<td>20</td>
<td>0.7</td>
<td>18</td>
<td>0.6</td>
<td>3</td>
<td>0.1</td>
<td>147</td>
</tr>
<tr>
<td>Lung</td>
<td>1173</td>
<td>80.0</td>
<td>162</td>
<td>11.0</td>
<td>61</td>
<td>4.2</td>
<td>6</td>
<td>0.4</td>
<td>3</td>
<td>0.2</td>
<td>4</td>
<td>0.3</td>
<td>58</td>
</tr>
<tr>
<td>NCORP</td>
<td>2145</td>
<td>74.4</td>
<td>216</td>
<td>7.5</td>
<td>52</td>
<td>1.8</td>
<td>12</td>
<td>0.4</td>
<td>3</td>
<td>0.1</td>
<td>11</td>
<td>0.4</td>
<td>445</td>
</tr>
<tr>
<td>Dev Therap</td>
<td>30</td>
<td>76.9</td>
<td>6</td>
<td>15.4</td>
<td>1</td>
<td>2.6</td>
<td>.</td>
<td>.</td>
<td>.</td>
<td>.</td>
<td>.</td>
<td>.</td>
<td>.</td>
</tr>
<tr>
<td>All Trials</td>
<td>22005</td>
<td>75.6</td>
<td>2895</td>
<td>9.9</td>
<td>2356</td>
<td>8.1</td>
<td>185</td>
<td>0.6</td>
<td>79</td>
<td>0.3</td>
<td>64</td>
<td>0.2</td>
<td>1513</td>
</tr>
</tbody>
</table>
Thank you for your attention!

General Session
NRG Oncology Semi-Annual Meeting
July 21, 2023